ASCP News
Statement on Behalf of the ASCP Leadership on Federally Proposed Reduction of Indirect Cost Rates on Federal Grants
The American Society for Clinical Psychopharmacology (ASCP) has learned with significant concern about the National Institutes of Health (NIH) plan, shared on February 7 and scheduled to become effective on February 10, to limit the indirect cost rate for biomedical...
Psychopharmacology is the scientific study of the use of pharmacological compounds in the treatment of mental disorders. Physicians and other prescribers with expertise in psychopharmacology apply their knowledge of pharmacokinetics (what the body does to medication) and pharmacodynamics (what the medications do to the body) in finding optimal medication regimens in treating mental health conditions such as depression, bipolar disorder, schizophrenia, post-traumatic stress disorder, etc.
OUR MEETINGS
ASCP organizes three major meetings per year. The Fall and Spring Update on Psychopharmacology: State of the Art meetings (East and West coast) bring together a number of outstanding psychopharmacologists to educate participants about the latest developments in the field.
The ASCP Annual Meeting brings together over 1200 academic and industry investigators, research pharmacists, clinicians and representatives from regulatory agencies to discuss newer treatments and facilitate collaborations.
Stay tuned for the 2025 ASCP Annual Meeting plenary speakers!
Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
The Journal of Clinical Psychiatry
JCP is an international peer-reviewed journal and the official publication of the ASCP. Founded in 1939, the journal is the leading resource providing clinical information on mental health topics to psychiatrists and other medical professionals while exploring newest advances in diagnosis and treatment. Current ASCP members receive an online subscription to the journal at Psychiatrist.com as part of their membership.
ASCP MEMBERSHIP
Founded in 1992, American Society of Clinical Psychopharmacology (ASCP) is a premier organization that works to advance the science, education and practice of clinical psychopharmacology. It comprises of over 1,200 members from all regions of the world, who are advocates for rational clinical psychopharmacology and for clinical research to develop better treatments to treat mental health conditions.